ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm
Executive Summary
The results of DESTINY-Breast04 could impact survival for approximately 50% of patients diagnosed with metastatic breast cancer today, principal investigator Modi said at the American Society of Clinical Oncology annual meeting.
You may also be interested in...
AstraZeneca Looks To Many Modalities In Cancer
Mohit Manrao, head of AstraZeneca’s US oncology business unit, explained the company’s diverse approach in an interview, including investments in ADCs, cell therapy and radiopharmaceuticals.
BioNTech Is Aggressively Advancing ADCs
The company, which brought in four antibody-drug conjugates last year through dealmaking, outlined development plans for its Phase III candidate during a Q4 sales and earnings call.
AstraZeneca/Daiichi Sankyo Line Up More Enhertu Indications
The high-profile antibody-drug conjugate has shown its potential to improve outcomes for heavily pre-treated patients in diseases such as bladder, cervical, pancreatic and rare cancers in a mid-stage trial.